A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

Фаза 2 Завершено NCT05039450

Заболевание	NASH - Nonalcoholic Steatohepatitis
Фаза	Фаза 2
Спонсор	Akero Therapeutics, Inc
Статус	Завершено
Участники	213 участн.
Вмешательство	EFX
Дата начала	30.07.2021
Дата завершения	15.12.2023
Публикация результатов	21.07.2026

Кратко

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.

Main: Change From Baseline in Fibrosis With no Worsening Steatohepatitis Assessed by NASH CRN System

Week 36 · Participants

Placebo (Main Study)	8 Participants
EFX 28 mg (Main Study)	10 Participants
EFX 50 mg (Main Study)	12 Participants
Placebo (Main Study)	49 Participants
EFX 28 mg (Main Study)	36 Participants
EFX 50 mg (Main Study)	39 Participants

p-value	0.3775
Point estimate percentage difference	6.73 (95% CI -8.77–22.24)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Va — Galectin Therapeutics Inc.
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease — Wake Forest University Health Sciences
Effect of Obesity on Proton Pump Inhibitors — Children's Mercy Hospital Kansas City
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatoti — Merck Sharp & Dohme LLC
Phase 2a Study of HPG1860 in Subjects With NASH — Hepagene (Shanghai) Co., Ltd.
Vitamin E Dosing Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.

English 한국어 日本語中文 Русский